May 14, 2020 — Modern clinical trials distribute samples to an expanding range of screening labs, specialty labs, and bio-banking facilities. Maintaining visibility into sample collection and data processing too often requires manually comparing inventories from each lab’s LIMS, and then checking against what is expected according to the protocol.
April 28, 2020 — COVID-19 is at the forefront of many research and development agendas. How can the integration of publicly available data help accelerate these efforts? The QuartzBio team is building and making available a unified SARS-CoV-2 / COVID-19 data ecosystem to support our own work and that of the broader research community. In […]
April 1, 2020 — The global pandemic caused by COVID-19 is presenting a public health crisis, and unprecedented challenges in the conduct of clinical trials. The quickly realized disruption has motivated FDA and EMA to issue guidance in direct response. As we continue to adapt to the new reality, we are seeing proactive monitoring of […]
March 19, 2020 — The global pandemic caused by SARS-CoV-2 presents a public health crisis, as well as unprecedented challenges in the conduct of clinical trials. Join us to learn how clinical teams are leveraging technology to quickly and efficiently gain visibility into their clinical samples across sites, labs, and storage facilities.
March 10, 2020 — In the years to come, public data will play an increasingly important role in drug discovery and development. In this brief, learn how biotechs are strategically using publicly available data to: Accelerate their path to the clinic by circumventing time-consuming, expensive data generation Increase the likelihood of success by mitigating the […]
February 4, 2019 — Pharmaceutical and healthcare organizations have zettabytes of data at their disposal, literally. They have spent the last decade accumulating information from electronic health records, insurance claims, lab results and more. Whatever frustrations one might have with the industry at large, it can’t reasonably be suggested that companies were caught unaware by […]
January 15, 2020 — With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success. The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), offers a […]
November 13, 2019 — Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in FLT3-ITD-positive R/R AML in the global, randomized, phase 3 QuANTUM-R study (Cortes et al. Lancet Oncol, 2019; NCT02039726). Patients with R/R FLT3-ITD-positive AML were randomized 2:1 to receive single agent quizartinib or […]
November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.
July 16, 2019 — Boston, MA — QuartzBio, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as […]
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.